Lifeward Ltd. (NASDAQ:LFWD) said it completed an initial financing that will inject about $5.6 million into the company, triggering a 5.6% rise in its shares during after-hours trading on Tuesday. The money was raised through senior secured convertible notes accompanied by warrants, and an additional $5.6 million tranche is conditionally available if specific commercial milestones are met.
The company executed a securities purchase agreement with institutional and accredited investors on July 6, 2026, under terms that form part of a previously announced strategic framework with Oramed Pharmaceuticals (NASDAQ:ORMP). That framework provides Lifeward access to up to $47 million in total financing; the company said the first $10 million of that arrangement has already been funded.
The incremental $5.6 million will be unlocked if Lifeward satisfies one of two clearly defined conditions: either a 150% increase in ReWalk unit sales measured over the trailing twelve-month period, or its common shares trading at or above $13.80 for ten consecutive trading days. The initial closing delivered the roughly $5.6 million in exchange for senior secured convertible notes and related warrants.
Company leadership framed the financing as evidence of investor confidence. Mark Grant, Lifeward’s President and Chief Executive Officer, said the proceeds will be used to bolster the company’s efforts to commercialize its restorative healthcare platform. According to the company, the capital will support expansion of its reimbursement-backed distribution model and further development of its product lineup.
Lifeward’s marketed products include the ReWalk Exoskeleton, the AlterG Anti-Gravity system, the MyoCycle FES System and the ReStore Exo-Suit. Separately, the company is advancing a Protein Oral Delivery platform aimed at enabling oral delivery of biologic drugs, with lead candidate ORMD-0801 directed at the diabetes market.
Market reaction and context
The after-hours share gain followed immediate disclosure of the financing terms and the milestone structure tied to commercial performance or sustained share-price thresholds. The arrangement with Oramed expands Lifeward’s potential funding runway while making additional capital contingent on operational or market achievements.